Cancer Screening Test
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Dec 11, 2008
app pub date -
Dec 15, 2006
filing date -
Dec 19, 2005
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The invention provides a cancer screening test, to identify patients having an increased likelihood of cancer, comprising the step of determining the presence or absence of members of a test group of tumour associated antigens in the blood of a patient. The test group comprises a plurality of tumour-associated antigens. Antigens of particular interest include Vascular Endothelial Growth Factor-A (VEGF A); CEA 125 (Carcinoembryonic antigen 125); Prostate Specific Antigen (PSA); CA15-3 (Cancer antigen 15-3); CA125 (Cancer Antigen 125); CYFRA21-1 (Cytokeratin-19 fragments); Soluble ectodomain of c-erbB2; CA27.29 (Cancer Antigen 27.29); IGF-I (Insulin-like growth factor-1); IGF-2 (Insulin-like growth factor-2); and IGFBP-3 (Insulin-like growth factor binding protein 3). The invention also provides an antibody-based test kit to implement the screening method.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully